# Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

> **NCT01696084** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 309 (actual)

## Conditions studied

- High Risk Acute Myeloid Leukemia

## Interventions

- **DRUG:** CPX-351
- **DRUG:** 7+3 (cytarabine and daunorubicin)

## Key facts

- **NCT ID:** NCT01696084
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-13
- **Primary completion:** 2015-12-31
- **Final completion:** 2015-12-31
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2020-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696084, "Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01696084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*